Article
Excerpt from the Press Release: ATHENS, Ga. and LOS GATOS, Calif., July 21, 2022 /PRNewswire/ — Blue Lake Biotechnology, Inc., a clinical-stage biotechnology company developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced the enrollment of the first participant in a Phase 1 clinical trial of their intranasal BLB-201 vaccine for RSV (respiratory syncytial virus)…
Read More
Approval recommended for first-line treatment of advanced melanoma patients with tumor cell PD-L1 expression < 1% Recommendation based on results from the Phase 2/3 RELATIVITY-047 trial, in which the fixed-dose combination of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab more than doubled median progression-free survival compared to nivolumab monotherapy If approved, it would…
Read More
Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two applications 90% survival rate following Epicel and/or Epicel plus split thickness skin graft Study demonstrates that standardized treatment protocols and surgical plans for…
Read More
Excerpt from the Press Release: LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a first-in-human clinical study to evaluate the pharmacokinetics and bioavailability of…
Read More
— If Granted by the European Commission, Veklury will Become the Only Direct-Acting Antiviral with Full Marketing Authorization in the EU — Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Commission (EC) adopted a positive…
Read More
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in…
Read More
-Topline Data expected in the last week of July- Excerpt from the Press Release: SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) — Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced data…
Read More
Royal Academy of Engineering MacRobert award-winner could transform lives of kidney disease patients, say experts Excerpt from the Press Release: A home dialysis machine inspired by technology used in fruit juice dispensers has won the UK’s most prestigious engineering prize. The device, made by Quanta, is currently used by about 50 patients in the UK,…
Read More
In a first, a patient in New Zealand has undergone gene-editing to lower their cholesterol. It could be the beginning of new era in disease prevention. Excerpt from the Press Release: A volunteer in New Zealand has become the first person to undergo DNA editing in order to lower their blood cholesterol, a step that…
Read More
— Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma — — First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sapanisertib in combination with telaglenastat in patients with non-small cell lung cancer — Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., July 13,…
Read More